Alnylam’s vutrisiran aces ATTR cardiomyopathy readout

Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up regulatory filings.